ES2942889T3 - Composiciones de plinabulina y uso de las mismas - Google Patents
Composiciones de plinabulina y uso de las mismas Download PDFInfo
- Publication number
- ES2942889T3 ES2942889T3 ES18768238T ES18768238T ES2942889T3 ES 2942889 T3 ES2942889 T3 ES 2942889T3 ES 18768238 T ES18768238 T ES 18768238T ES 18768238 T ES18768238 T ES 18768238T ES 2942889 T3 ES2942889 T3 ES 2942889T3
- Authority
- ES
- Spain
- Prior art keywords
- inhibitor
- plinabulin
- immunotherapy
- administered
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762470802P | 2017-03-13 | 2017-03-13 | |
| US201862621528P | 2018-01-24 | 2018-01-24 | |
| PCT/US2018/022064 WO2018169887A1 (en) | 2017-03-13 | 2018-03-12 | Compositions of plinabulin and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2942889T3 true ES2942889T3 (es) | 2023-06-07 |
Family
ID=63522552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18768238T Active ES2942889T3 (es) | 2017-03-13 | 2018-03-12 | Composiciones de plinabulina y uso de las mismas |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200129504A1 (enExample) |
| EP (2) | EP4190326A1 (enExample) |
| JP (3) | JP7280192B2 (enExample) |
| KR (1) | KR102659907B1 (enExample) |
| CN (1) | CN110603037A (enExample) |
| AU (2) | AU2018236168B2 (enExample) |
| BR (1) | BR112019018880A2 (enExample) |
| CA (1) | CA3056077A1 (enExample) |
| DK (1) | DK3595653T3 (enExample) |
| ES (1) | ES2942889T3 (enExample) |
| NZ (1) | NZ757213A (enExample) |
| SG (1) | SG11201908420WA (enExample) |
| WO (1) | WO2018169887A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102626155B1 (ko) | 2015-03-06 | 2024-01-17 | 비욘드스프링 파마수티컬스, 인코포레이티드. | Ras 돌연변이와 관련된 암의 치료 방법 |
| JP6904570B2 (ja) | 2015-03-06 | 2021-07-21 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 脳腫瘍の治療方法 |
| AU2016291708B2 (en) | 2015-07-13 | 2020-12-24 | Beyondspring Pharmaceuticals, Inc | Plinabulin compositions |
| EP3413885A4 (en) | 2016-02-08 | 2019-09-18 | Beyondspring Pharmaceuticals, Inc. | COMPOSITIONS WITH TUCARESOL OR ITS ANALOG |
| SG11201810872UA (en) | 2016-06-06 | 2019-01-30 | Beyondspring Pharmaceuticals Inc | Composition and method for reducing neutropenia |
| US11633393B2 (en) | 2017-01-06 | 2023-04-25 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| US11400086B2 (en) | 2017-02-01 | 2022-08-02 | Beyondspring Pharmaceuticals, Inc. | Method of reducing chemotherapy-induced neutropenia |
| GB201713760D0 (en) * | 2017-08-28 | 2017-10-11 | Univ Leuven Kath | Treatment of epilepsy |
| JP7350015B2 (ja) | 2018-01-24 | 2023-09-25 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | プリナブリンの投与による血小板減少症を軽減するための組成物および方法 |
| WO2019232257A1 (en) * | 2018-06-01 | 2019-12-05 | Beyondspring Pharmaceuticals, Inc. | Composition and method of treating cancer associated with egfr mutation |
| GB201913988D0 (en) | 2019-09-27 | 2019-11-13 | Celleron Therapeutics Ltd | Novel treatment |
| JP2022552011A (ja) * | 2019-10-15 | 2022-12-14 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 鉄障害を処置するための方法及び組成物 |
| IL297884A (en) * | 2020-05-04 | 2023-01-01 | Beyondspring Pharmaceuticals Inc | Triple combination therapy to increase cancer cell killing in cancers with low immunogenicity |
| KR102428863B1 (ko) * | 2020-08-11 | 2022-08-03 | 서울대학교병원 | 자가면역 뇌염 발생 가능성 예측을 위한 정보 제공 방법 |
| WO2022133492A1 (en) * | 2020-12-18 | 2022-06-23 | Beyondspring Pharmaceuticals, Inc. | Compositions and methods for generating anti-tumor immune response |
| WO2022216908A1 (en) | 2021-04-09 | 2022-10-13 | Beyondspring Pharmaceuticals, Inc. | Therapeutic compositions and methods for treating tumors |
| CN113456643B (zh) * | 2021-08-11 | 2022-04-01 | 遵义医科大学 | 一种含普那布林的药物组合及其应用 |
| WO2023154755A1 (en) * | 2022-02-10 | 2023-08-17 | Beyondspring Pharmaceuticals, Inc. | Stable plinabulin formulations and methods of their preparation and use |
| CN117860672A (zh) | 2022-10-11 | 2024-04-12 | 大连万春布林医药有限公司 | 一种普那布林胶束组合物及其制备方法 |
| WO2025006507A1 (en) * | 2023-06-27 | 2025-01-02 | Beyondspring Pharmaceuticals, Inc. | Oncology combination therapy and methods of use |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| US4919934A (en) | 1989-03-02 | 1990-04-24 | Richardson-Vicks Inc. | Cosmetic sticks |
| US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
| US6737042B2 (en) | 2001-05-24 | 2004-05-18 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
| US7919497B2 (en) * | 2002-08-02 | 2011-04-05 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| US7935704B2 (en) * | 2003-08-01 | 2011-05-03 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
| US7064201B2 (en) * | 2002-08-02 | 2006-06-20 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
| BRPI0506655A (pt) * | 2004-02-04 | 2007-05-08 | Nereus Pharmaceuticals Inc | dehidrofenilahistinas e seus análogos, e sìntese de dehidrofenilahistinas e seus análogos |
| TW200711649A (en) * | 2005-06-17 | 2007-04-01 | Combinatorx Inc | Combination therapy for the treatment of immunoinflammatory disorders |
| EP1926724A1 (en) * | 2005-09-21 | 2008-06-04 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| WO2012035436A1 (en) * | 2010-09-15 | 2012-03-22 | Tokyo University Of Pharmacy And Life Sciences | Plinabulin prodrug analogs and therapeutic uses thereof |
| JP6311097B2 (ja) * | 2013-07-31 | 2018-04-18 | 学校法人東京薬科大学 | 微小管脱重合剤 |
| CA2926771C (en) * | 2013-10-11 | 2022-07-05 | Beyondspring Pharmaceuticals, Inc. | Cancer treatment with combination of plinabulin and taxane |
| US20180028531A1 (en) | 2015-02-12 | 2018-02-01 | BeyondSpring Phamaceuticals, Inc. | Use of plinabulin in combination with immune checkpoint inhibitors |
| EP3413885A4 (en) * | 2016-02-08 | 2019-09-18 | Beyondspring Pharmaceuticals, Inc. | COMPOSITIONS WITH TUCARESOL OR ITS ANALOG |
-
2018
- 2018-03-12 CA CA3056077A patent/CA3056077A1/en active Pending
- 2018-03-12 SG SG11201908420W patent/SG11201908420WA/en unknown
- 2018-03-12 JP JP2019550138A patent/JP7280192B2/ja active Active
- 2018-03-12 BR BR112019018880A patent/BR112019018880A2/pt active Search and Examination
- 2018-03-12 US US16/493,271 patent/US20200129504A1/en not_active Abandoned
- 2018-03-12 AU AU2018236168A patent/AU2018236168B2/en active Active
- 2018-03-12 EP EP23153650.9A patent/EP4190326A1/en not_active Withdrawn
- 2018-03-12 EP EP18768238.0A patent/EP3595653B1/en active Active
- 2018-03-12 NZ NZ757213A patent/NZ757213A/en unknown
- 2018-03-12 ES ES18768238T patent/ES2942889T3/es active Active
- 2018-03-12 DK DK18768238.0T patent/DK3595653T3/da active
- 2018-03-12 WO PCT/US2018/022064 patent/WO2018169887A1/en not_active Ceased
- 2018-03-12 CN CN201880029191.0A patent/CN110603037A/zh active Pending
- 2018-03-12 KR KR1020197029387A patent/KR102659907B1/ko active Active
-
2023
- 2023-05-11 JP JP2023078735A patent/JP2023099217A/ja active Pending
-
2024
- 2024-02-06 AU AU2024200709A patent/AU2024200709A1/en not_active Abandoned
-
2025
- 2025-07-04 JP JP2025113816A patent/JP2025138849A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019018880A2 (pt) | 2020-04-14 |
| DK3595653T3 (da) | 2023-04-17 |
| WO2018169887A1 (en) | 2018-09-20 |
| AU2018236168A1 (en) | 2019-10-10 |
| AU2024200709A1 (en) | 2024-02-22 |
| JP2023099217A (ja) | 2023-07-11 |
| CN110603037A (zh) | 2019-12-20 |
| EP3595653A4 (en) | 2020-11-11 |
| EP3595653A1 (en) | 2020-01-22 |
| AU2018236168B2 (en) | 2024-02-29 |
| KR20190122822A (ko) | 2019-10-30 |
| JP2020520889A (ja) | 2020-07-16 |
| KR102659907B1 (ko) | 2024-04-24 |
| NZ757213A (en) | 2022-01-28 |
| EP4190326A1 (en) | 2023-06-07 |
| SG11201908420WA (en) | 2019-10-30 |
| CA3056077A1 (en) | 2018-09-20 |
| JP2025138849A (ja) | 2025-09-25 |
| US20200129504A1 (en) | 2020-04-30 |
| JP7280192B2 (ja) | 2023-05-23 |
| EP3595653B1 (en) | 2023-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2942889T3 (es) | Composiciones de plinabulina y uso de las mismas | |
| AU2020245520B2 (en) | Topical formulations for treatment of peripheral neuropathies | |
| US20130190341A1 (en) | High bioavailability opioid formulations | |
| US20120322767A1 (en) | Formulations of bisphosphonates and vitamin d suiutable for intermittent intramuscular and subcutaneous administration | |
| JP2015042658A (ja) | 局所使用のためのビタミンｋ類似体製剤 | |
| US9381246B2 (en) | Cancer therapy | |
| US20220152033A1 (en) | Compositions and methods for deep dermal drug delivery | |
| US11065206B2 (en) | Topical formulations including lipid microcapsule delivery vehicles and their uses | |
| HK40020654B (en) | Compositions of plinabulin and use thereof | |
| HK40020654A (en) | Compositions of plinabulin and use thereof | |
| JP2022515569A (ja) | フェノルドパムの安定な局所用組成物 | |
| US20230181591A1 (en) | Stable formulations of shr0302 | |
| US20240226068A9 (en) | Topical Formulation of Disease-Modifying Antirheumatic Drug (DMARDs) for the Treatment of Rheumatoid Arthritis, Melanoma, Squamous Cell Carcinoma, Atopic Dermatitis, and Psoriasis | |
| Nam | Transdermal delivery of risedronate using chemical enhancers for improved skin penetration | |
| WO2025229186A1 (en) | Composition for use in reducing the risk of recurrent acute urinary retention | |
| PL196371B1 (pl) | Preparat dermatologiczny do stosowania miejscowego |